Pregnancy Outcomes in the Omalizumab Pregnancy Registry and a Disease-matched Comparator Cohort.

There was no evidence of an increased risk of major congenital anomalies among pregnant women exposed to omalizumab compared to a disease-matched unexposed cohort. Given the observational nature of this registry, however, an absence of increased risk with omalizumab cannot be definitively established.